Advanced search
Publication Cover
Pharmaceutical Development and Technology Volume 17, 2012 - Issue 2
Submit an article Journal homepage
171
Views
10
CrossRef citations to date
0
Altmetric
Research Article

In vitro and in vivo evaluation of a hydrogel-based prototype transdermal patch system of alfuzosin hydrochloride

Anroop B. NairM. M. College of Pharmacy, M. M. University, Ambala, India
,
Siva Ram Kiran VakaDepartment of Pharmaceutics, The University of Mississippi, University, MS, USA
,
Sumit GuptaM. M. College of Pharmacy, M. M. University, Ambala, India
,
Michael A. RepkaDepartment of Pharmaceutics, The University of Mississippi, University, MS, USA
&
S. Narasimha MurthyDepartment of Pharmaceutics, The University of Mississippi, University, MS, USACorrespondence[email protected]
Pages 158-163 | Received 09 Aug 2010, Accepted 23 Aug 2010, Published online: 19 Oct 2010

References

  • Carbone DJ Jr, Hodges S. Medical therapy for benign prostatic hyperplasia: Sexual dysfunction and impact on quality of life. Int J Impotence Res 2003;15:299–306.
  • Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474–479.
  • Roehrborn CG, Rosen RC. Medical therapy options for aging men with benign prostatic hyperplasia: Focus on alfuzosin 10 mg once daily. Clin Interv Aging 2008;3:511–524.
  • Tammela T. Benign prostatic hyperplasia. Practical treatment guidelines. Drugs Aging 1997;10:349–366.
  • Lepor H. Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol 2007;9:181–190.
  • Giuliano F. Lower urinary tract symptoms and sexual dysfunction: A common approach. BJU Int 2008;101:22–26.
  • Wilde MI, Fitton A, McTavish D. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs 1993;45:410–429.
  • Lee M. Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia. Am J Health Syst Pharm 2003;60:1426–1439.
  • Weiner DM, Lowe FC. Alfuzosin for the management of benign prostate hyperplasia. Expert Opin Pharmacother 2003;4:2057–2063.
  • Vallancien G, Emberton M, Alcaraz A, Matzkin H, van Moorselaar RJ, Hartung R, Harving N, Elhilali M. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: A 3-year experience in real-life practice. BJU Int 2008;101:847–852.
  • Kongkanand A, Chodchoy V, Lojanapiwat B, Pumpaisanchai S, Ratana-Olarn K, Sae-Tang P, Taweemonkongsap T. Safety and efficacy of a prolonged-release formulation of alfuzosin 10 mg once daily in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. J Med Assoc Thai 2009;92:969–978.
  • Zabala S, Thomson C, Valdearcos S, Gascón A, Pina MA. Alfuzosin-induced hepatotoxicity. J Clin Pharm Ther 2000;25:73–74.
  • Yolcu OF, Köklü S, Köksal AS, Yüksel O, Beyazit Y, Basar O. Alfuzosin-induced acute hepatitis in a patient with chronic liver disease. Ann Pharmacother 2004;38:1443–1445.
  • Kim SY, Kim BH, Dong SH, Kim HJ, Chang YW, Chang R, Kim YW. Alfuzosin-induced acute liver injury. Korean J Hepatol 2007;13:414–418.
  • Barry BW. Mode of action of penetration enhancers in human skin. J Control Release 1987;6:85–97.
  • Sinha VR, Kaur MP. Permeation enhancers for transdermal drug delivery. Drug Dev Ind Pharm 2000;26:1131–1140.
  • Kandavilli S, Nair V, Panchagnula R. Polymers in transdermal drug delivery systems. Pharm. Technol 2002;26:62–80.
  • Valenta C, Auner BG. The use of polymers for dermal and transdermal delivery. Eur J Pharm Biopharm 2004;58:279–289.
  • Hoare TR, Kohane DS. Hydrogels in drug delivery: Progress and challenges. Polymer 2008;49:1993–2007.
  • Siegel SJ, Neill CO, Dube LM, Kaldeway P, Morris R, Jackson D, Sebree T. A unique iontophoretic patch for optimal transdermal delivery of sumatriptan. Pharm Res 2007;24:1919–1926.
  • Banga AK, Chien YW. Hydrogel-based iontophoretic delivery devices for transdermal delivery of peptide/protein drugs. Pharm Res 1993;10:697–702.
  • Phipps JB, Padmanabhan RV, Lattin GA. Iontophoretic delivery of model inorganic and drug ions. J Pharm Sci 1989;78:365–369.
  • Fang J, Huang Y, Wu P, Tsai Y. Transdermal iontophoresis of sodium nonivamide acetate II: Optimization and evaluation on solutions and gels. Int J Pharm 1996;145:175–186.
  • Kanikkannan N. Iontophoresis based transdermal delivery systems. Biodrugs 2002;16:339–347.
  • Murthy SN, Sen A, Hui SW. Surfactant-enhanced transdermal drug delivery by electroporation. J Control Release 2004;98:307–315.
  • Murthy SS, Vaka SRK, Mathur SK, Murthy, SN. Noninvasive transcutaneous sampling of glucose by Electroporation. J Diabetes Sci Technol 2008;2:250–254.
  • Singh P, Maibach HI. Iontophoresis in drug delivery: Basic principles and applications. Crit Rev Ther Drug Carrier Syst 1994;11:161–213.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.